2015 American Transplant Congress
Monitoring Intracellular Tacrolimus Concentration in Kidney Transplant Recipients With Stable Graft Function
Background: Monitoring the intracellular concentration of immunosuppressive agents can be promising to improve and individualize clinical practice in patients receiving transplantation. However, this issue remains…2015 American Transplant Congress
Acute Kidney Injury in the MELD Era of Liver Transplantation. Are Calcineurin Inhibitors So Problematic for Renal Function?
Acute kidney injury(AKI)after liver transplantation (LT) is common.Calcineurin inhibitors(CNI)have to be well-balanced.The aims were analyze the specific effect of CNI on AKI in a cohort…2015 American Transplant Congress
Cyclosporine Nephrotoxicity Is Associated With Diminished Expression of Heat Shock Protein 27 (HSP27) and Loss of Claudin-2-Dependent Intercellular Adhesion
1Medicine, University of Alabama at Birmingham, Birmingham, AL; 2INSERM U1082, Poitiers, France.
Although Cyclosporine A (CsA), a calcineurin inhibitor (CNI), is an effective immunosuppressant used to prevent kidney allograft rejection, prolonged administration is frequently associated with kidney…2015 American Transplant Congress
A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan
The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…2015 American Transplant Congress
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors are frequently delayed to allow for recovery of renal function after transplantation; however, there is a paucity of literature supporting a delay…2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…2015 American Transplant Congress
Primary and Secondary Vaccine Responses in a Non-Human Primate Model of Cardiac Allotransplantation
Purpose: To compare the effect of calcineurin- versus costimulation-based immunosuppression on primary and secondary vaccine responses in non-human primate heart transplant recipients.Background: Antibody response following…2015 American Transplant Congress
Intrapatient Variability of Tacrolimus Blood Concentrations Following Renal Transplant – Acute Rejection or No Connection?
Background: A high degree of intrapatient variability (IPV) of tacrolimus blood concentrations has been associated with poor long-term outcome (1). Periods of under-exposure with increased…2015 American Transplant Congress
Incidence, Determinants and Outcome of Kidney Transplantation for End Stage Renal Disease After Heart Transplantation
Objectives: Progressive renal failure is a frequent complication following heart transplantation (HTx), is generally attributed to calcineurin inhibitor (CNI) based immunosuppression, and may result in…2015 American Transplant Congress
New Insights in Clinical and Genetic Determinants of Longitudinal Dose-Corrected CNI Exposure in Children After Renal Transplantation
Purpose: Calcineurin-inhibitors (CNI) have a narrow therapeutic index and dosing is difficult due to inter- and intra-individual variation in pharmacokinetics (PK). Polymorphisms in genes involved…
American Transplant Congress abstracts